These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15557613)

  • 21. Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions.
    Launois P; Gumy A; Himmelrich H; Locksley RM; Röcken M; Louis JA
    J Immunol; 2002 May; 168(9):4628-35. PubMed ID: 11971011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
    Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
    Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo.
    Stetson DB; Mohrs M; Mallet-Designe V; Teyton L; Locksley RM
    Immunity; 2002 Aug; 17(2):191-200. PubMed ID: 12196290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice.
    Launois P; Maillard I; Pingel S; Swihart KG; Xénarios I; Acha-Orbea H; Diggelmann H; Locksley RM; MacDonald HR; Louis JA
    Immunity; 1997 May; 6(5):541-9. PubMed ID: 9175832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leishmania major LACK antigen is required for efficient vertebrate parasitization.
    Kelly BL; Stetson DB; Locksley RM
    J Exp Med; 2003 Dec; 198(11):1689-98. PubMed ID: 14657221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.
    Bertholet S; Debrabant A; Afrin F; Caler E; Mendez S; Tabbara KS; Belkaid Y; Sacks DL
    Infect Immun; 2005 Oct; 73(10):6620-8. PubMed ID: 16177338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
    Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
    Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of Leishmania major by a monoclonal alpha beta T cell repertoire.
    Reiner SL; Fowell DJ; Moskowitz NH; Swier K; Brown DR; Brown CR; Turck CW; Scott PA; Killeen N; Locksley RM
    J Immunol; 1998 Jan; 160(2):884-9. PubMed ID: 9551925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population.
    von der Weid T; Beebe AM; Roopenian DC; Coffman RL
    J Immunol; 1996 Nov; 157(10):4421-7. PubMed ID: 8906817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-cell outgrowth and ligand-specific production of IL-10 correlate with Th2 dominance in certain parasitic diseases.
    Palanivel V; Posey C; Horauf AM; Solbach W; Piessens WF; Harn DA
    Exp Parasitol; 1996 Nov; 84(2):168-77. PubMed ID: 8932766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12.
    Himmelrich H; Parra-Lopez C; Tacchini-Cottier F; Louis JA; Launois P
    J Immunol; 1998 Dec; 161(11):6156-63. PubMed ID: 9834101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of CD86 in BALB/c mice infected with Leishmania major does not prevent the expansion of low avidity T cells.
    Moro M; Filippi C; Gallard A; Malherbe L; Foucras G; Akiba H; Yagita H; Guéry JC; Glaichenhaus N
    Eur J Immunol; 2002 Dec; 32(12):3566-75. PubMed ID: 12516542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production.
    Ronet C; Hauyon-La Torre Y; Revaz-Breton M; Mastelic B; Tacchini-Cottier F; Louis J; Launois P
    J Immunol; 2010 Jan; 184(2):886-94. PubMed ID: 19966209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.
    Menon JN; Bretscher PA
    Eur J Immunol; 1996 Jan; 26(1):243-9. PubMed ID: 8566074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections.
    Kostka SL; Knop J; Konur A; Udey MC; von Stebut E
    J Invest Dermatol; 2006 Jul; 126(7):1582-9. PubMed ID: 16645594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate.
    McSorley SJ; Rask C; Pichot R; Julia V; Czerkinsky C; Glaichenhaus N
    Eur J Immunol; 1998 Feb; 28(2):424-32. PubMed ID: 9521049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.